Dassault Systèmes: Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
Medidata, a Dassault Systèmes brand, announced that Eisai Inc. has selected its AI-driven Clinical Data Studio to enhance clinical trial efficiency and patient experience. The solution aims to accelerate data review and reconciliation by 80%. Eisai will use this innovative data experience to gain better control over clinical data, execute complex trials, and improve patient experience.
Clinical Data Studio, powered by the Medidata Platform, centralizes management of all data sources, improving data reliability across the clinical trial ecosystem. It integrates data from Medidata and non-Medidata sources, streamlining the import process and enabling automatic validation. The AI-driven solution offers up to 80% faster data review and provides a comprehensive view of patient data for concurrent review, visualization, and action.
Medidata, un marchio di Dassault Systèmes, ha annunciato che Eisai Inc. ha selezionato il suo Clinical Data Studio alimentato dall'IA per migliorare l'efficienza delle sperimentazioni cliniche e l'esperienza del paziente. La soluzione mira ad accelerare la revisione e la riconciliazione dei dati del 80%. Eisai utilizzerà questa esperienza innovativa sui dati per avere un maggiore controllo sui dati clinici, eseguire studi complessi e migliorare l'esperienza dei pazienti.
Clinical Data Studio, alimentato dalla Piattaforma Medidata, centralizza la gestione di tutte le fonti di dati, migliorando l'affidabilità dei dati nell'ecosistema delle sperimentazioni cliniche. Integra dati provenienti da sorgenti Medidata e non, semplificando il processo di importazione e abilitando la validazione automatica. La soluzione guidata dall'IA offre fino all'80% di revisione dei dati più rapida e fornisce una visione completa dei dati dei pazienti per una revisione, visualizzazione e azione contemporanee.
Medidata, una marca de Dassault Systèmes, anunció que Eisai Inc. ha seleccionado su Clinical Data Studio impulsado por IA para mejorar la eficiencia de los ensayos clínicos y la experiencia del paciente. La solución tiene como objetivo acelerar la revisión y reconciliación de datos en un 80%. Eisai utilizará esta innovadora experiencia de datos para obtener un mejor control sobre los datos clínicos, realizar ensayos complejos y mejorar la experiencia del paciente.
Clinical Data Studio, impulsado por la Plataforma Medidata, centraliza la gestión de todas las fuentes de datos, mejorando la fiabilidad de los datos en el ecosistema de ensayos clínicos. Integra datos de fuentes Medidata y no Medidata, simplificando el proceso de importación y habilitando la validación automática. La solución impulsada por IA ofrece una revisión de datos hasta un 80% más rápida y proporciona una vista integral de los datos del paciente para revisión, visualización y acción simultáneas.
메디데이터(Medidata), 다쏘 시스템즈(Dassault Systèmes)의 브랜드가 에사이(Eisai Inc.)가 임상 시험 효율성과 환자 경험을 향상시키기 위해 AI 기반의 Clinical Data Studio를 선택했다고 발표했습니다. 이 솔루션은 데이터 검토 및 조정을 80% 가속화하는 것을 목표로 합니다. 에사이는 이 혁신적인 데이터 경험을 통해 임상 데이터에 대한 더 나은 통제력을 확보하고, 복잡한 시험을 수행하며, 환자 경험을 개선할 것입니다.
Clinical Data Studio는 메디데이터 플랫폼에 의해 구동되며, 임상 시험 생태계 전반에 걸쳐 모든 데이터 소스 관리를 중앙 집중화하여 데이터 신뢰성을 향상시킵니다. 메디데이터 및 비 메디데이터 출처의 데이터를 통합하여 가져오기 프로세스를 간소화하고 자동 검증을 가능하게 합니다. AI 기반 솔루션은 데이터 검토를 최대 80% 더 빠르게 제공하며, 동시 검토, 시각화 및 조치를 위한 포괄적인 환자 데이터 뷰를 제공합니다.
Medidata, une marque de Dassault Systèmes, a annoncé qu'Eisai Inc. a choisi son Clinical Data Studio alimenté par l'IA pour améliorer l'efficacité des essais cliniques et l'expérience des patients. La solution vise à accélérer la révision et la réconciliation des données de 80%. Eisai utilisera cette expérience de données innovante pour obtenir un meilleur contrôle sur les données cliniques, exécuter des essais complexes et améliorer l'expérience utilisateur des patients.
Clinical Data Studio, propulsé par la plateforme Medidata, centralise la gestion de toutes les sources de données, améliorant la fiabilité des données dans l'écosystème des essais cliniques. Il intègre des données provenant de sources Medidata et non Medidata, simplifiant ainsi le processus d'importation et permettant une validation automatique. La solution alimentée par l'IA offre une révision des données jusqu'à 80% plus rapide et fournit une vue d'ensemble des données des patients pour une révision, une visualisation et une action simultanées.
Medidata, eine Marke von Dassault Systèmes, hat angekündigt, dass Eisai Inc. ihr KI-gesteuertes Clinical Data Studio ausgewählt hat, um die Effizienz klinischer Studien und das Patientenerlebnis zu verbessern. Die Lösung zielt darauf ab, die Datenüberprüfung und -abstimmung um 80% zu beschleunigen. Eisai wird diese innovative Datenerfahrung nutzen, um eine bessere Kontrolle über klinische Daten zu gewinnen, komplexe Studien durchzuführen und das Patientenerlebnis zu verbessern.
Clinical Data Studio, betrieben durch die Medidata-Plattform, zentralisiert das Management aller Datenquellen und verbessert die Datenzuverlässigkeit im gesamten Ökosystem klinischer Studien. Es integriert Daten aus Medidata- und Nicht-Medidata-Quellen, vereinfacht den Importprozess und ermöglicht eine automatische Validierung. Die KI-gesteuerte Lösung bietet bis zu 80% schnellere Datenprüfung und bietet eine umfassende Sicht auf Patientendaten für gleichzeitige Überprüfung, Visualisierung und Maßnahmen.
- Eisai selects Medidata's Clinical Data Studio, potentially improving trial efficiency
- AI-enhanced solution aims to accelerate data review and reconciliation by 80%
- Clinical Data Studio offers up to 80% faster data review
- Integration of diverse data sources may improve data reliability and trial management
- None.
Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
AI-enhanced solution will help Eisai accelerate data review and reconciliation by
New York – July 25, 2024 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience.
“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”
Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on.
“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
About Eisai Inc.
Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S. operations include research & development; manufacturing; global supply & logistics; and commercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn.
Contact:
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
Medidata.AR@3ds.com
Attachment
FAQ
What is the purpose of Eisai selecting Medidata's Clinical Data Studio for DASTY?
How does Clinical Data Studio impact data management for DASTY?
What are the key features of Medidata's Clinical Data Studio for DASTY?
How does Clinical Data Studio address data challenges in clinical trials for DASTY?
